8-K: Henry Schein Reports Solid Q1 2024 Results, Tightens Full-Year Sales Guidance

Henry Schein announced solid first-quarter 2024 financial results, driven by gross margin expansion and recovery from a previous cyber incident, while also tightening its full-year sales growth guidance.

Summary

• Henry Schein reported a 3.7% increase in total net sales for the first quarter of 2024, reaching $3.2 billion.
• Internal sales decreased by 1.8%, which includes a 300 to 400 basis points decrease due to the residual impact of a cyber incident and a 60 basis point decrease due to lower PPE sales.
• GAAP net income was $93 million, or $0.72 per diluted share, compared to $121 million, or $0.91 per diluted share, in the first quarter of 2023.
• Non-GAAP net income was $143 million, or $1.10 per diluted share, compared to $161 million, or $1.21 per diluted share, in the same period last year.
• Adjusted EBITDA for the quarter was $255 million, consistent with the $256 million reported in the first quarter of 2023.
• The company repurchased approximately 1 million shares of its common stock at an average price of $75.10 per share, totaling approximately $75 million.
• Henry Schein has tightened its 2024 total sales growth guidance to 8% to 10%, down from the previous 8% to 12% range.
• The company affirmed its 2024 non-GAAP diluted EPS guidance of $5.00 to $5.16 and 2024 Adjusted EBITDA growth of more than 15%.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to solid earnings, recovery from the cyber incident, and reaffirmed guidance, but tempered by the decrease in internal sales and tightened sales growth guidance.

Positives

• The company achieved solid earnings driven by gross margin expansion.
• There was a strong recovery from the previous cyber incident.
• The company is making good progress on executing its BOLD+1 Strategic Plan.
• Recent acquisitions are contributing positively to the results.
• The company has a strong pipeline of new specialty products and software innovation.

Negatives

• Internal sales decreased by 1.8% due to the cyber incident and lower PPE sales.
• GAAP net income decreased from $121 million to $93 million year-over-year.
• Non-GAAP net income decreased from $161 million to $143 million year-over-year.
• The company has tightened its total sales growth guidance for 2024.

Risks

• The company is still experiencing residual impacts from the previous cyber incident.
• Lower PPE sales, primarily due to lower glove pricing, are negatively impacting sales.
• The company faces risks related to its dependence on third-party manufacturers and suppliers.
• There are risks associated with the development and protection of new products and technologies.
• The company faces transitional challenges associated with acquisitions, dispositions, and joint ventures.
• The company is exposed to security risks associated with its information systems and technology products, including cyberattacks.
• The company operates in a highly competitive and consolidating market.
• The company is subject to changes in the healthcare industry and regulatory requirements.
• The company is exposed to risks associated with global operations, litigation, and economic conditions.

Future Outlook

The company expects 2024 total sales growth to be approximately 8% to 10% and affirms its 2024 non-GAAP diluted EPS guidance of $5.00 to $5.16 and 2024 Adjusted EBITDA growth of more than 15%.

Management Comments

• Our first-quarter financial results reflect solid earnings driven by gross margin expansion and a strong recovery from last quarters cyber incident, said Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein.
• We continue to make good progress on executing our BOLD+1 Strategic Plan and are pleased with the contribution from our recent acquisitions.
• Our projected sales growth reflects continued recovery from last years cyber incident and a strong pipeline of new specialty products and software innovation.

Industry Context

This announcement reflects the ongoing recovery of healthcare providers from recent challenges, including cyber incidents, and the continued focus on technology and value-added services in the healthcare industry. The company's performance is indicative of the broader trends in the healthcare distribution sector, where companies are focusing on operational efficiency and strategic acquisitions.

Comparison to Industry Standards

• Henry Schein's 3.7% total sales growth is moderate compared to some of its peers in the healthcare distribution industry, which have seen higher growth rates due to increased demand for medical supplies and equipment.
• Companies like McKesson and Cardinal Health, which are also major players in healthcare distribution, have reported varying growth rates, with some segments experiencing higher growth than others.
• The impact of the cyber incident on Henry Schein's internal sales is a unique factor that distinguishes its performance from competitors who did not experience similar disruptions.
• The company's focus on technology and value-added services aligns with industry trends, as healthcare providers increasingly seek solutions that improve operational efficiency and clinical outcomes.
• The adjusted EBITDA growth guidance of more than 15% is a positive indicator, suggesting that the company is managing its costs effectively and is on track to improve profitability.

Stakeholder Impact

• Shareholders will be impacted by the financial results and the updated guidance.
• Employees may be affected by restructuring costs and the ongoing strategic initiatives.
• Customers will benefit from the company's focus on new products and software innovation.
• Suppliers will be impacted by the company's purchasing decisions and supply chain management.
• Creditors will be interested in the company's financial health and ability to meet its obligations.

Next Steps

• The company will hold a conference call to discuss the first-quarter 2024 financial results.
• The company will continue to execute its BOLD+1 Strategic Plan.
• The company will focus on continued recovery from the cyber incident and the development of new specialty products and software innovation.

Key Dates

Keywords

financial results, sales growth, cyber incident, EPS, EBITDA, healthcare solutions, dental, medical, technology, acquisitions, stock repurchase, guidance